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Abstract
Objective The objective of this study was to investigate
whether total lesion glycolysis (TLG) and metabolic tumor
volume (MTV) measured by 18F-fluorodeoxyglucose (18F-
FDG) positron emission tomography/computed tomogra-
phy (PET/CT) could predict the aggressiveness and lymph
node metastasis (LNM) in patients with incidentally
detected differentiated thyroid carcinoma.
Methods A total 358 patients with focal FDG-avid thy-
roid incidentaloma during cancer evaluation were enrolled.
Among 235 patients in whom fine-needle aspiration biopsy
was performed, 51 patients underwent total thyroidec-
tomy with LN dissection. We analyzed the relationship
between volume-based parameters and clinicopathologic
characteristics.
Results The mean age and tumor size were 57.1 ±
11.3 years and 1.15 ± 0.81 cm, respectively. The prevalence
of malignancy was 21.7 % (51/235). When SUVmax[ 5.91,
MTV2.5[ 2.05 cm3, and TLG2.5[ 9.09 were used as cut-
off points, sensitivity, specificity, and area under curve (AUC)
for prediction of lateral LNM were 77.9, 69.1 %, 0.716
(P = 0.047), 77.8, 88.1 %, 0.839 (P\ 0.001), 77.8, 85.1 %,
and 0.815 (P = 0.002), respectively. However, MTV and
TLG had no value in prediction of central LNM, extrathy-
roidal extension, and multifocality. On comparison ROC
curve analysis, the MTV and TLG showed the statistical dif-
ferences for the prediction of lateral LNM compared with
SUVmax (all P’s\ 0.05).
Conclusions This study has shown for the first time that
volume-based PET functional parameters had a significant
value for the prediction of lateral LNM in incidentally
detected PTC. These results suggest that higher MTV and
TLG can be potential new risk factors for preoperative risk
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preoperative risk stratification in patients with PTC needs
to be confirmed in further large studies.
Keywords Metabolic tumor volume  Total lesion
glycolysis  Papillary thyroid carcinoma  Lymphatic
metastasis
Introduction
Fluorodeoxyglucose labeled with 18Fluorine (18F-FDG)
positron emission tomography/computed tomography
(PET/CT) has an advantage over conventional modalities
such as CT or magnetic resonance imaging (MRI) in that it
enables quantification of the metabolic activity of a tumor.
Functional imaging of FDG PET/CT can provide metabolic
information on malignant tissues and make it possible to
reflect the tumor burden more accurately [1]. Therefore,
volume-based PET parameters such as metabolic tumor
volume (MTV) and total lesion glycolysis (TLG) have
been developed to measure metabolic activity in an entire
tumor mass [1, 2].
MTV is a semi-quantitative parameter of metabolic
activity of tumors determined by 18F-FDG PET/CT images.
MTV potentially has clinical value in the evaluation of
tumor biology, evaluation of response to treatment, and
prognostication in various cancers [3–6]. As another semi-
quantitative parameter, TLG is called the Larson–Ginsberg
index, which was calculated by multiplying the mean
standardized uptake value (SUVmean) by the MTV. TLG
corresponds to the cell mass of the target lesion associated
with FDG uptake. TLG has been suggested to better reflect
global metabolic activity in whole tumors [1]. Thus, TLG
have the potential to become valuable imaging biomarkers
in human solid tumors as prognostic biomarkers, adding
value to clinical staging, for treatment response assessment
and for treatment optimization [7].
Preoperative detection of lateral lymph node metastasis
(LNM) in differentiated thyroid carcinoma (DTC) was very
important for surgical plan. In addition, lateral LNM of
DTC may reflect the biological aggressiveness of the car-
cinoma [8]. LNM may be preoperatively evaluated by
imaging tests including ultrasonography (US), CT, mag-
netic resonance imaging (MRI), and PET/CT. Although US
is the most routinely recommended of these imaging
methods for preoperative evaluation of LNM in patients
with papillary thyroid carcinoma (PTC) [9, 10], no other
study has attempted to adapt volume-based PET parame-
ters such as TLG and MTV for prediction of lateral LNM
and characterization of DTC. The objective of this study
was to investigate whether TLG and MTV measured by
18F-FDG PET/CT could predict the aggressiveness and
lateral LNM in patients with incidentally detected DTC.
Materials and methods
Patients
From August 2010 to April 2013, 18,172 subjects (7589
men and 10583 women) with known or suspected cancer
and healthy people in Pusan National University Hospital
were enrolled in the current study. The purpose of 18F-
FDG PET/CT scan was as follows: initial staging of the
cancer in 9064, treatment response determination in
5186, detection of recurrent and metastatic diseases in
3306, evaluation for cancer of unknown primary origin
in 383, and screening for health checkup in 233 subjects.
This study was approved by the Institutional Review
Board of Pusan National University Hospital, and all
subjects gave their informed consent to participate in the
study.
Three hundred fifty eight patients (374 nodules) have
focal FDG-avid thyroid nodule in 18F-FDG PET/CT scan.
Among these 358 patients, cytological diagnosis with fine-
needle aspiration biopsy (FNAB) was performed in 235
patients. The results of FNAB were 36 malignant, 12
suspicious malignant, 4 follicular neoplasm, 13 atypia of
undetermined significance (AUS), 153 benign, and 17
nondiagnostic. However, 101 patients did not receive
FNAB due to underlying cancer, general condition, and
follow-up loss. In addition, US was performed in 22
patients without FNAB due to typical benign ultrasono-
graphic features. All 48 patients with FNAB results of
malignant or suspicious malignant who underwent total
thyroidectomy and central lymph node dissection were
surgically confirmed as PTC. Two AUS nodules and one
follicular neoplasm were confirmed as PTC and minimally
invasive follicular thyroid carcinoma (FTC) by surgery,
respectively. All lateral LNM had been localized by US
and confirmed by FNAB prior to surgery. Especially,
thirteen patients (20 lateral LNs) have FDG-avid lateral
lymph node in 18F-FDG PET/CT scan. Among these
patients, 9 patients underwent lateral LN dissection for
lateral LN metastasis confirmed by preoperative US-guided
FNA with Tg assay. The prevalence of malignancy was
21.7 % (51/235). Finally, we analyzed 51 patients in this
study.
18F-FDG PET-CT imaging
18F-FDG PET/CT images were obtained with a dedicated
PET-CT scanner (Biograph 40, SIEMENS, Knoxville, TN,
USA). Standard patient preparation included at least 8-hour
fasting and a serum glucose level of less than 6.6 mmol/L
before 18F-FDG administration. PET/CT imaging was
performed 60 min after injection of 18F-FDG (5 MBq per
kilogram of body weight). CT scan (120 kV, 30 mA) with
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slice width of 4 mm was obtained before the PET acqui-
sition for attenuation correction. Emission scan time per
bed position was 3 min; six bed positions were acquired.
PET data were obtained using a high-resolution whole-
body scanner with an axial field of view of 21.6 cm. The
average axial resolution varied between 2.0 mm full width
at half maximum in the center and 2.4 mm at 28 cm. The
average total PET-CT examination time was 20 min.
18F-FDG PET/CT image analysis
PET/CT data sets were evaluated by 2 nuclear physicians
blinded to all imaging studies and clinical and pathologic
results. Decisions concerning the analysis of 18F-FDG PET/
CT data sets were reached by consensus. In 18F-FDG PET/
CT images, thyroid uptake was considered to be present
when there was increased uptake in the thyroid gland above
physiologic background. Focal thyroid uptake was defined
as FDG uptake in less than one lobe of the thyroid gland.
This definition was used in an attempt to separate patients
with thyroiditis such as Hashimoto’s thyroiditis, which
usually manifests with diffuse FDG thyroid uptake [11].
When focal FDG activity was seen in the thyroid region, the
fused images and the CT images were evaluated to ensure
that uptake was from within the thyroid gland. In addition, if
there were multiple thyroid nodules in focal FDG uptake
lesions in both thyroid glands, we evaluated the largest
thyroid nodule with focal intense FDG uptake. There was no
artifact from the clavicle encountered in PET/CT image.
The PET/CT data sets were analyzed semi-quantita-
tively by the use of the maximum standardized uptake
value (SUVmax) of
18F-FDG uptake. Semi-quantitative
evaluation was performed with a syngo Multimodality
Workplace (MMWP) ( Siemens AG.) The SUVmax and
SUVmean were semi-quantitatively used to determine
18F-
FDG avidity. The SUVs were determined by the region-of-
interest technique. SUVmean was defined as the mean tumor
concentration of FDG (kBq/mL) divided by the injected
dose (kBq), corrected for patient body weight(g). To cal-
culate SUVmax, manually defined circular regions of
interest (ROI) were drawn on the attenuation-corrected
emission images throughout the axial plane in which a
suspicious lesion could be delineated.
Measurement of metabolic tumor volume and total
lesion glycolysis on 18F-FDG PET/CT
MTV and TLG were obtained with each threshold of SUV
as 2.5, 3.0, 3.5, and 4.0.
We drew the volume of interest(VOI), which showed
equal or greater than absolute SUV of 2.5, 3.0, 3.5, and 4.0
on each axial image of PET-CT. MTV was determined
using a fixed background SUV cutoff, all voxels containing
SUV values above this threshold constituting the MTV.
The VOI was drawn so as to include hypermetabolic thy-
roid nodule. The boundaries were drawn large enough to
include the thyroid tumor in the PET images. The con-
touring margins around the target lesion of thyroid were
automatically produced. The voxels presenting SUV
intensity of equal or greater than each threshold of the
SUVmax of the primary tumor on each axial image of PET/
CT were incorporated to define the MTV.
As previously described [12], after all hypermetabolic
tumor foci were segmented, MTV was calculated by
summation of all the voxels of each slice of PET/CT. If
SUVmax of the primary tumor was lower than that of the
threshold, we regarded the MTV of the lesion as 0. We did
not use point spread function (PSF) reconstruction algo-
rithm for determination of MTV in this study. TLG was
calculated by multiplying the SUVmean value of the tumor
by the MTV of the tumor.
Statistical analysis
Statistical analyses were performed using commercially
available software (MedCalc 12.3, Mariakerke, Belgium).
Continuous data are expressed as mean ± SD for normally
distributed values and median (range) for nonparametric
values (skewed variables). Categorical data were presented
as frequency and percentage. Receiver operating charac-
teristic (ROC) analyses were performed to determine the
optimal cutoff values of MTV and TLG yielding the
maximal sensitivity and specificity for prediction of
pathologic lateral LN metastasis of thyroid cancer. ROC
curves for each parameter were derived and evaluated by
comparing the areas under the curve (AUCs). Patients were
classified into two groups, namely those with low and high
values of SUVmax, MTV, and TLG according to ROC
cutoff values. Various volumetric parameters and clinico-
pathologic characteristics were evaluated using the Chi-
square test or Fisher’s exact test between lateral LN posi-
tive and negative, as appropriate. To compare the semi-
quantitative indices according to tumor size, we performed
Kruskal–Wallis tests. We used comparison ROC curve
analysis to test the statistical significance of the difference
among the parameters of F-18 FDG PET-CT. Statistical
significance was defined as P\ 0.05.
Results
Patient characteristics
Patient and tumor characteristics are shown in Table 1. The
mean age was 57.1 ± 11.3 years (range 34–88 years). The
mean tumor size was 1.15 ± 0.81 cm (range 0.4–4.5). The
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proportion of patients with papillary thyroid microcarcinoma
(PTMC) was 68 % (34/50) with the exception of one mini-
mally invasive FTC. According to the pathologic results, the
lateral LNM was present in 9 of 51 patients (17.6 %). The
proportion of advanced American Joint Committee on Can-
cer (AJCC) stage (stage III and IV) was 62.0 % (31/50).
Comparison of semi-quantitative indices according
to pathologic tumor size
Figure 1 demonstrates the differences of SUVmax and
MTV according to pathologic tumor size. The medians
of SUVmax and MTV2.5 were significantly higher in
patients who had a tumor greater than 1.5 cm in size as
compared to those who had a tumor B1.5 cm in size
(P\ 0.001).
Association of FDG uptake of lateral lymph node
and FNA results of lateral lymph node
Table 2 shows the association between FDG uptake of
lateral LN and US-guided FNA results. Among 51
patients, twenty lateral LNs with FDG uptake were
detected in 13 patients (25.5 %). The mean number of
FDG uptake of lateral LN per patients was 1.54 ± 0.66
(range 1–3). The sensitivity, specificity, accuracy, positive
predictive value (PPV), and negative predictive value
(NPV) of FDG uptake for lateral LNM were 66.7, 83.0,
80.4, 46.2, and 92.1 %, respectively. However, three
patients who had US-guided FNA-confirmed lateral LNM
did not show FDG uptake in lateral LNs on F18-FDG
PET/CT.
ROC analyses of SUVmax and volume-based
parameters for poor pathologic characteristics
The ability of the SUVmax, MTV, and TLG of the primary
tumor to predict poor pathologic characteristics including
central LNM, extrathyroidal extension (ETE), and multi-
focality was depicted by the ROC curve. When SUVmax
[ 4.6 was used as the cutoff point, the area under curve
(AUC) for prediction of central LNM was 0.576 (95 % CI
0.429–0.713) (P = 0.361). When SUVmax[ 6.68 was
used as the cutoff point, the AUC for prediction of ETE
was 0.589 (95 % CI 0.442–0.724) (P = 0.292). When
SUVmax[ 9.07 was used as the cutoff point, the AUC for
prediction of multifocality was 0.511 (95 % CI
0.367–0.653) (P = 0.909). The MTV had no predictive
value in central LNM (AUC = 0.535, P = 0.679),
ETE (AUC = 0.571, P = 0.401), and multifocality
(AUC = 0.501, P = 0.992). In addition, the TLG had
no predictive value in central LNM (AUC = 0.536,
Table 1 Clinical characteristics of the patients
Characteristics Value
Total number of patients 51
Age, year, mean ± SD (range) 57.1 ± 11.3 (34–88)
No. of women (%) 45 (88.2)
Tumor size, cm, mean ± SD (range) 1.15 ± 0.81 (0.4–4.5)
SUVmax, median (range) 5.67 (1.99–52.25)
MTV2.5, cm3, median (range) 0.95 (0–29.35)
MTV3, cm3, median (range) 0.72 (0–26.44)
MTV3.5, cm3, median (range) 0.51 (0–24.86)
MTV4, cm3, median (range) 0.39 (0–23.25)
TLG2.5, median (range) 3.98 (0–407.08)
TLG3, median (range) 3.34 (0–398.98)
TLG3.5, median (range) 2.80 (0–393.78)
TLG4, median (range) 1.99 (0–387.58)
Multifocality (%) 16 (31.4)
Extrathyroidal extension (%) 23 (45.1)
LN metastasis (%) 26 (51.0)
Lateral LN metastasis (%) 9 (17.6)
Advanced stage (%)a 30 (62.0)
Data are expressed as mean ± SD and median (range) for continuous
variables and frequency (%) for categorical variables
SUV standardized uptake value, MTV metabolic tumor volume, TLG
total lesion glycolysis
a Advanced stage, TNM stage III and IV
Fig. 1 The differences of semi-
quantitative parameters
(a SUVmax, b MTV2.5)
according to tumor size
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P = 0.664), ETE (AUC = 0.607, P = 0.199), and multi-
focality (AUC = 0.510, P = 0.914).
Comparison of clinicopathologic characteristics
and semi-quantitative metabolic parameters
according to lateral lymph node metastasis
Table 3 shows the comparison between SUVmax, MTV,
TLG, and various clinical characteristics, including age,
tumor size, ETE, central LNM, and multifocality according
to lateral LNM. Lateral LN metastases were common in the
group of tumor greater than 1 cm in size (P = 0.020) and
central LNM group (P = 0.047). However, there was no
significant difference of age (P = 0.947), sex (P = 0.140),
ETE (P = 0.268), and multifocality (P = 0.701) between
two groups. The lateral LNM group showed statistically
significant higher values of SUVmax (P = 0.020), all MTV
(all P’s\ 0.001), and all TLG (all P’s\ 0.001) than those
of the lateral LN-negative group.
Table 3 Comparison of clinicopathologic characteristics and semi-
quantitative metabolic parameters according to lateral lymph node
metastasis
Variables Lateral lymph node metastasis P
Negative number (%) Positive number (%)
Age (years)
[45 37 (82.2) 8 (17.8) 0.947
B45 5 (83.3) 1 (16.7)
Sex
Male 12 (70.6) 5 (29.4) 0.140
Female 30 (88.2) 4 (11.8)
Tumor size (cm)
[1 13 (65.0) 7 (35.0) 0.020
B1 29 (93.5) 2 (6.5)
ETE
Presence 17 (73.9) 6 (26.1) 0.268
Absence 25 (89.3) 3 (10.7)
CLN
Presence 17 (70.8) 7 (29.2) 0.047
Absence 25 (92.6) 2 (7.4)
Multifocality
Presence 14 (87.5) 2 (12.5) 0.701
Absence 28 (80.0) 7 (20.0)
SUVmax
[5.91 13 (65.0) 7 (35.0) 0.020
B5.91 29 (93.5) 2 (6.5)
MTV2.5 (cm3)
[2.05 5 (41.7) 7 (58.3) 0.000
B2.05 37 (94.7) 2 (5.3)
MTV3 (cm3)
[1.54 5 (41.7) 7 (58.3) 0.000
B1.54 37 (94.7) 2 (5.3)
MTV3.5 (cm3)
[1.22 5 (41.7) 7 (58.3) 0.000
B1.22 37 (94.7) 2 (5.3)
MTV4 (cm3)
[0.61 7 (50.0) 7 (50.0) 0.001
B0.61 35 (94.6) 2 (5.4)
TLG2.5
[9.09 6 (46.2) 7 (53.8) 0.000
B9.09 36 (94.7) 2 (5.3)
TLG3
[5.35 7 (50.0) 7 (50.0) 0.001
B5.35 35 (94.6) 2 (5.4)
TLG3.5
[4.42 7 (50.0) 7 (50.0) 0.001
B4.42 35 (94.6) 2 (5.4)
TLG4
[3.47 7 (50.0) 7 (50.0) 0.001
B3.47 35 (94.6) 2 (5.4)
Data are expressed as frequency (%) for categorical variables
CLN central lymph node, ETE extrathyroidal extension, SUV stan-
dardized uptake value, MTV metabolic tumor volume, TLG total
lesion glycolysis
Table 2 Association of FDG uptake of lateral lymph node and
ultrasonography-guided FNA results in patients with FDG positivity









1 Rt. II 3.4 Reactive
2 Lt. II 5.3 Metastasis
Lt. III 16.0 Metastasis
3 Rt.IB 4.7 Metastasis
4 Lt.II 3.5 Reactive
Lt.III 3.1 Metastasis
5 Rt.IB 3.6 Reactive
6 Rt.III 7.0 Reactive
7 Rt.II 3.8 Reactive
Lt.II 3.2 Reactive
8 Lt.V 12.7 Reactive
9 Lt.III 3.1 Reactive
10 Rt.II 6.8 Metastasis
Lt.II 4.0 Metastasis
11 Lt.II 4.6 Reactive
12 Rt.II 9.2 Metastasis
Rt.IV 11.6 Metastasis
Rt.III 2.8 Metastasis
13 Lt.II 10.3 Metastasis
Lt.III 5.8 Metastasis
The classification of cervical lymph nodes from consensus statement
on the terminology and classification of central neck dissection for
thyroid cancer. 2009 The American Thyroid Association Surgery
Working Group
FDG fluorodeoxyglucose, LN lymph node, FNA fine-needle aspira-
tion, SUV standardized uptake value
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Prediction of lateral lymph node metastasis
from semi-quantitative metabolic parameters
of primary thyroid carcinoma
ROC analyses were performed to determine the optimal
cutoff values of semi-quantitative indices for prediction of
pathologic lateral LN involvement of thyroid carcinoma.
Table 4 and Fig. 2 summarize the results of ROC analyses.
The AUC for predicting lateral LNM with SUVmax was
0.716 (P = 0.047). The AUCs for predicting lateral LNM
with MTV calculated at 2.5, 3.0, 3.5, and 4.0 of fixed
SUVmax threshold were 0.839 (P\ 0.001), 0.825
(P = 0.002), 0.815 (P = 0.002), and 0.798 (P = 0.003),
respectively. The AUCs for predicting lateral LNM with
TLG calculated at 2.5, 3.0, 3.5, and 4.0 of fixed SUVmean
threshold were 0.815 (P = 0.002), 0.802 (P = 0.003),
0.802 (P = 0.003), and 0.790 (P = 0.004), respectively.
Therefore, we used the MTV2.5 and TLG2.5 showing the
lowest P value and the highest AUC for prediction of lat-
eral LNM (Fig. 2).
Comparison of ROC curve analysis
Table 5 shows the results of pairwise comparison of ROC
analyses of semi-quantitative parameters of 18F-FDG PET/
CT for prediction of pathologic lateral LNM of thyroid
carcinoma. Compared with SUVmax, the MTV2.5 and
TLG2.5 showed the statistical differences for the prediction
of pathologic lateral LNM of thyroid carcinoma (MTV vs.
SUVmax P\ 0.0125, TLG vs. SUVmax P = 0.0133).
However, there was no significant difference between
MTV2.5 and TLG2.5 (P = 0.1298).
Discussion
The value of preoperative F18-FDG PET/CT in PTC
remains unclear. As one of the candidate predictors for the
evaluation of lateral LNM and local invasiveness of DTC,
we evaluated whether the volume-based parameters of 18F-
FDG PET/CT imaging could predict pathologic lateral
LNM and aggressiveness in patients with incidentally
detected DTC in this study. The current study demonstrated
that the SUVmax, MTV, and TLG measured by
18F-FDG
PET/CT had significant association with lateral LNM in
patients with incidentally detected DTC. The MTV and
TLG had significant value for the prediction of pathologic
lateral LNM in comparison with SUVmax.
It is well known that PTC generally shows an indolent
disease course. However, PTC frequently metastasizes or
recurs to regional LN. Metastasis to lateral LN is asso-
ciated with a poor prognosis [13–15]. Thus, imaging the
neck before surgery for thyroid carcinoma is necessary to
determine the appropriate extent of surgical resection. In
addition, it is important to identify patients who are at
risk of developing distant metastasis or recurrence that
necessitate more aggressive surgical treatment or more
intensive radioactive iodine (RAI) therapy. In this regard,
18F-FDG PET/CT scans provide anatomical as well as
prognostic information that can identify the patients at
higher risk of recurrence and metastatic disease [16, 17].
However, 18F-FDG PET/CT is not routinely used in daily
clinical practice in characterizing thyroid nodules and
preoperative investigation of thyroid carcinomas. It is
well known that US is useful in the preoperative assess-
ment of cervical LN metastasis in patients with DTC.
Very recently, Lee et al. [10] demonstrated that
Table 4 Optimal cutoff values of SUVmax and volumetric parameters for prediction of the lateral lymph node metastasis
Criteria Cutoff value Sensitivity (95 % CI) Specificity (95 % CI) AUC (95 % CI) SE P value
SUVmax 5.91 77.9 % (40.0–97.2 %) 69.1 % (52.9–82.4 %) 0.716 (0.572–0.833) 0.109 0.047
MTV (cm3)
MTV2.5 2.05 77.8 % (40.0–97.2 %) 88.1 % (74.4–96.0 %) 0.839 (0.709–0.927) 0.099 \0.001
MTV3 1.54 77.8 % (40.0–97.2 %) 88.1 % (74.4–96.0 %) 0.825 (0.693–0.917) 0.104 0.002
MTV3.5 1.22 77.8 % (40.0–97.2 %) 88.1 % (74.4–96.0 %) 0.815 (0.681–0.909) 0.101 0.002
MTV4 0.61 77.8 % (40.0–97.2 %) 83.3 % (68.6–93.0 %) 0.798 (0.662–0.897) 0.101 0.003
TLG
TLG2.5 9.09 77.8 % (40.0–97.2 %) 85.7 % (71.5–94.6 %) 0.815 (0.681–0.910) 0.099 0.002
TLG3 5.35 77.8 % (40.0–97.2 %) 83.3 % (68.6–93.0 %) 0.802 (0.666–0.900) 0.103 0.003
TLG3.5 4.42 77.8 % (40.0–97.2 %) 83.3 % (68.6–93.0 %) 0.802 (0.666–0.900) 0.101 0.003
TLG4 3.47 77.8 % (40.0–97.2 %) 83.3 % (68.6–93.0 %) 0.790 (0.653–0.891) 0.099 0.004
AUC area under curve, CI confidence interval, MTV metabolic tumor volume (cm3), SE standard error, TLG total lesion glycolysis
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preoperative US might be helpful in detecting nodal
metastases in PTC patients.
The value of FDG uptake in preoperative risk stratifi-
cation remains controversial. In this study, 25.5 % (13/51)
of patients showed FDG uptake in lateral LN. Increased
FDG uptake of lateral LN metastasis showed low sensi-
tivity and PPV but high specificity and NPV for patho-
logically proven lateral LNM. Although three patients who
had US-guided FNA-confirmed lateral LN metastasis did
not show FDG uptake in lateral LNs on F18-FDG PET/CT,
preoperative FDG negativity of lateral LNs suggested low
possibility in lateral LNM in patients with DTC. Therefore,
both preoperative F18-FDG PET-CT and US may improve
sensitivity and specificity of prediction of lateral LNM in
incidentally detected thyroid carcinoma.
A previous study showed that the SUV of thyroid car-
cinoma alone was not predictive of the presence of ETE,
Fig. 2 Receiver operating characteristic curves (ROC) using a SUVmax, b metabolic tumor volume (MTV), and c total lesion glycolysis (TLG)
to predict lateral lymph node metastasis
Table 5 Pairwise comparison of ROC curves of semi-quantitative










95 % CI -0.0069 to 0.0546
P 0.1298
DBA difference between areas, CI confidence interval, MTV meta-
bolic tumor volume, SE standard error, SUV standardized uptake
value, TLG total lesion glycolysis
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LNM, or the multiplicity of PTMC [18]. In contrast, Yun
et al. [19] reported that visual FDG positivity is a potential
new risk factor that may be useful for preoperative risk
stratification of PTMC. Gender, age, and tumor size
showed a correlation with either ETE or central LNM,
while visually discernible FDG uptake was associated with
a higher prevalence of ETE and central LNM. However, in
the current study, all parameters measured by 18F-FDG
PET/CT had no value in prediction of central LNM, ETE,
and multifocality except lateral LNM. In particular, the
MTV and TLG were better predictors of lateral LNM than
SUVmax. When all patients were classified into two groups
according to the presence of lateral LNM, tumor size
greater than 1 cm and central LNM were significantly
associated with lateral LNM. However, other clinico-
pathologic characteristics including age, gender, ETE, and
multifocality showed no significant difference between the
two groups.
It is well established that ETE is an important adverse
prognostic factor for patients with PTC [20, 21]. However,
recent studies reported that microscopic ETE might not be
a prognostic factor to predict tumor recurrence in patients
with PTC [22, 23]. Thus, it is unclear that microscopic ETE
is associated with poor prognostic factor. No significant
predictive value of volume-based parameters for ETE
observed in the current study is thought to be that most
ETE in our patients (22/23) is minimal microscopic
extrathyroidal invasion into the strap muscle.
It is still unclear whether or not FDG positivity of DTC
in the preoperative 18F-FDG PET-CT indicates tumor
aggressiveness. The reason of the discrepancy between
previous studies [4–7] and our findings in DTC could be
that tumor size of incidentally detected PTC was relatively
small compared to other cancers. The partial volume effect
(PVE) can have a major effect on the measurement of
tumor uptake with PET. The PVE may affect MTV or TLG
[24]. The PVE strongly depends on the size of the tumor.
The smaller the tumor, the greater the underestimation of
the uptake value [25]. In addition, the accuracy of PET-
based automatic or semiautomatic delineation methods can
be affected by many factors, including image resolution
and reconstruction settings [26, 27].
This study has some limitations. First, all patients with
focal FDG-avid thyroid incidentaloma did not underwent
FNAB and surgery to confirm malignancy due to under-
lying cancer and general condition. Second, the limited
sample size of surgically confirmed DTC and the retro-
spective design are also limitations of this study. Third, a
large proportion of the patients studied in this series have
had former cancer treatment which might have influenced
measured metabolic parameters. Despite these limitations,
we have, for the first time, found the clinical implication
of volume-based parameters of 18F-FDG PET/CT in
preoperative risk stratification of incidentally detected
thyroid cancers.
In conclusion, this study has shown that volume-based
PET functional parameters such as TLG and MTV can
provide metabolic information of incidentally detected
PTC. The TLG and MTV had significant value for the
prediction of lateral LNM in comparison with SUVmax.
These results suggest that higher MTV and TLG can be
potential new risk factors for preoperative risk stratifica-
tion. Therefore, thyroid cancer with high MTV and TLG
should be closely examined for LNM by preoperative neck
US. Future large prospective studies will provide greater
clarity regarding the value of these parameters of preop-
erative 18F-FDG PET-CT in patients with incidentally
detected DTC.
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